Home - Products-JKN Signaling Pathways-Iptacopan

Iptacopan

CAS:

1644670-37-0

Cat No:

JKN00169

Purity:

98%

Inquire Now + Next Product +

Note: All products of the company are for scientific research only, and do not provide products and services for any individual

LNP023 (Iptacopan) — Oral Complement Factor B Inhibitor for Research & Drug Development

LNP023, also known as Iptacopan, is a potent, orally bioavailable complement Factor B inhibitor. It selectively targets the alternative complement pathway, providing a valuable tool for mechanistic research, drug discovery, and preclinical studies of complement-mediated diseases. JKN Biochem offers high-purity LNP023 suitable for laboratory research, pharmaceutical R&D, and CRO procurement.

Key Features & Research Advantages

● Orally bioavailable small molecule with high selectivity for complement Factor B

● Potent inhibitory activity in vitro and in vivo, supporting mechanistic studies and drug evaluation

● High-purity compound (>98%) with stringent QC for batch-to-batch consistency

● Flexible supply: from milligrams to multi-gram quantities for lab and commercial research

Mechanism of Action

LNP023 selectively inhibits complement Factor B, preventing formation of the C3 convertase complex and downstream complement activation. This targeted inhibition is essential for studies of paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy, C3 glomerulopathy, and other complement-mediated disorders. The oral bioavailability of LNP023 allows for convenient experimental administration in preclinical models.

Research & Preclinical Applications

● Factor B inhibition in vitro and in vivo for complement pathway research

● Preclinical models: modulation of complement activation markers and hemolysis studies

● Supports drug discovery pipelines targeting complement-mediated diseases

Why Choose JKN Biochem for LNP023?

● Global B2B supplier of high-quality research compounds and APIs

● Flexible supply scales for lab procurement and pharmaceutical R&D

● Strict QC with full batch documentation for reproducibility

● Responsive technical support and reliable international shipping

Product Description

CAS	1644670-37-0	Cat No	JKN00169
Name	Iptacopan
Synonyms	LNP023
Smiles	O=C(O)C1=CC=C([C@H]2N(CC3=C(OC)C=C(C)C4=C3C=CN4)CC[C@H](OCC)C2)C=C1
Chemical Name	4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid
Formula	422.520	MWt	C25H30N2O4
Purity	98%	Storage	Store at 4--8℃
Description	Iptacopan, also known as LNP023, is a complement Factor B Inhibitor (IC50=10 nM). LNP023 improves LN in MRL/lpr mice. The mechanism is as follows: LNP023 binds to CFB to inhibit the activation of the alternative complement pathway. LNP023 treatment for LN may also play a role in regulating the protein expression of AKT, TNF-α, and STST3. LNP023 showed low clearance and high bioavailability (62.2%). Furthermore, four minor metabolites from rat plasma were detected and identified by LC combined with high-resolution mass spectrometry. The metabolic pathways were O-deethylation (M1), hydroxylation (M4), oxidation (M3), and acyl-glucuronidation (M2).

Product Documents

Products Category